» Articles » PMID: 24265525

Prospective Observation of 5-year Clinical Course of Subclinical Hypothyroidism in Korean Population

Overview
Specialty General Medicine
Date 2013 Nov 23
PMID 24265525
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Subclinical hypothyroidism (SCH) is a common clinical condition, whereas it's natural course has not been identified distinctly. We evaluated the natural history of 169 SCH patients over 5-yr and the prognostic factors including thyroid autoantibodies and thyroid ultrasonographic (USG) findings related to develop overt hypothyroidism. After 5 yr, 47.3% of patients showed normalization of TSH, while 36.7% of patients remained persistence of high level of TSH, and overt hypothyroidism developed in 11.2% of patients. There were painless thyroiditis (2.9%) and hyperthyroidism (1.7%) during 5 yr follow-up. The thyroid nodule was seen in 48.6% of patients. Most of patients had 1 to 2 nodules whereas only 3% of patients with thyroid nodule had more than 6 nodules. Overt hypothyroidism patients had more heterogenous echogenecity in USG compared to patients with normalization or persistent SCH (76.5% vs 50.0% vs 35.0%, P = 0.048) and higher prevalence positive anti-thyroid peroxidase (anti-TPO Ab) and anti-thyroglobulin antibody (anti-Tg Ab) and titer of anti-TPO Ab than other two groups. The cut off values for prediction of overt hypothyroidism were TSH > 7.45 µIU/mL, free T4 < 1.09 ng/dL and Anti-TPO Ab > 560 IU/mL. SCH has various courses and initial TSH, free T4, presence of thyroid autoantibody, titer of thyroid autoantibody; and thyroid USG findings can serve as a prognostic factor for progression of overt hypothyroidism. These parameters suggest consideration to initiate thyroid hormone treatment in SCH.

Citing Articles

Association of longitudinal changes in serum lipids with the natural history of subclinical hypothyroidism: A retrospective cohort study using data from the REACTION study.

Zhong F, Guan Q, Zhang H, Zhang X, Zhao M, Yuan Z EClinicalMedicine. 2022; 53:101629.

PMID: 36060516 PMC: 9433604. DOI: 10.1016/j.eclinm.2022.101629.


Natural history of subclinical hypothyroidism and prognostic factors for the development of overt hypothyroidism: Tehran Thyroid Study (TTS).

Amouzegar A, Dehghani M, Abdi H, Mehran L, Masoumi S, Azizi F J Endocrinol Invest. 2022; 45(12):2353-2364.

PMID: 35925467 DOI: 10.1007/s40618-022-01876-6.


Comparison of Five Different Criteria for Diagnosis of Subclinical Hypothyroidism in a Large-Scale Chinese Population.

Zheng Y, Dong S, Gong Y, Wang J, Wang F, Zeng Q Front Endocrinol (Lausanne). 2022; 13:820414.

PMID: 35242111 PMC: 8887626. DOI: 10.3389/fendo.2022.820414.


A model of functional thyroid disease status over the lifetime.

Dzierlenga M, Allen B, Ward P, Clewell 3rd H, Longnecker M PLoS One. 2019; 14(7):e0219769.

PMID: 31318913 PMC: 6638952. DOI: 10.1371/journal.pone.0219769.

References
1.
Imaizumi M, Sera N, Ueki I, Horie I, Ando T, Usa T . Risk for progression to overt hypothyroidism in an elderly Japanese population with subclinical hypothyroidism. Thyroid. 2011; 21(11):1177-82. DOI: 10.1089/thy.2010.0411. View

2.
Samuels M, Schuff K, Carlson N, Carello P, Janowsky J . Health status, mood, and cognition in experimentally induced subclinical hypothyroidism. J Clin Endocrinol Metab. 2007; 92(7):2545-51. DOI: 10.1210/jc.2007-0011. View

3.
Cooper D . Clinical practice. Subclinical hypothyroidism. N Engl J Med. 2001; 345(4):260-5. DOI: 10.1056/NEJM200107263450406. View

4.
Cooper D, Halpern R, WOOD L, Levin A, Ridgway E . L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med. 1984; 101(1):18-24. DOI: 10.7326/0003-4819-101-1-18. View

5.
Canaris G, Manowitz N, Mayor G, Ridgway E . The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160(4):526-34. DOI: 10.1001/archinte.160.4.526. View